Shubham Mathur

Dr. Shubham Mathur

Tel Aviv University
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2021 in Journal of the World Aquaculture Society
Verified
Journal Article
Open access
PDF file
DBDaniel Benetti
Daniel Benetti
JSJorge Suarez
Jorge Suarez
JCJulio Camperio
Julio Camperio
RHRonald H. Hoenig
Ronald H. Hoenig
CTCarlos E. Tudela
Carlos E. Tudela
JSJohn D. Stieglitz
John D. Stieglitz
Cobia, Rachycentron canadum, is an important species for aquaculture worldwide. Production technology from egg to market was established in the early 1990s and continues to be perfected to this day. This species exhibits extraordinary scope for growth and can reach between 4 and 8 kg in 1 year, with females growing almost twice as fast and large as males. Despite continuous progress in maturation, spawning, larval rearing, fingerling production, nutrition, health management, genetics, and growout technology, overall cobia aquaculture production worldwide has been slow in the last decade. One of the biggest challenges remains the development of practical commercial feeds that are ecologically and economically efficient for this species. Feed conversion ratios are still very high, ranging from 2.0 to 3.0:1. In addition to nutritional challenges, diseases such as Photobacterium, Amyloodinium ocellatus, and Brooklynella hostilis continue to impact cobia aquaculture production worldwide. Genetics and breeding programs for cobia are still at their infancy. We report on current status of cobia breeding efforts as well as on advances on developing female monosex populations to exploit the sexually dimorphic growth in this species. Nutrition, health, and genetics will be the greatest drivers to improve overall performance and increases in production of the cobia aquaculture industry.

17 February 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
Shubham MathurShubham Mathur
Shubham Mathur
MBMenachem Banai
Menachem Banai
DCDani Cohen
Dani Cohen
Vaccination against brucellosis using live attenuated strains is the primary approach in protecting livestock against the disease through a strong cellular immune response. Attenuated vaccine strains also induce serum anti-Brucella antibodies, mostly against Brucella O-polysaccharide, but their role in protection against the disease remains unclear. In this study, we show that Brucella OPS serum antibodies after vaccination or natural infection could kill Brucella in vitro as shown by the serum bactericidal activity (SBA) assay. We used serum samples of Rev. 1 vaccinated sheep that were negative or positive for Brucella OPS antibodies by either one of complement fixation test (CFT), microplate agglutination test (MAT) and ELISA, or sera of naturally infected sheep positive by CFT. We found a significant increase in the killing ability of sera 30 days after intraocular vaccination with Rev. 1 as compared with pre-vaccination. SBA was significantly higher in sera containing Brucella OPS IgG antibodies in comparison with sera lacking such antibodies (p < 0.001 against 16M & Rev. 1 strains). All 10 sera of convalescent sheep demonstrated significant killing ability against the 16M B. melitensis field strain. Specific OPS antibodies participate in the in vitro complement mediated Brucella killing suggesting a potential role in protection against the disease through this mechanism and relevance of developing OPS-based Brucella vaccines.

Verified
Journal Article
Open access
PDF file
DKDavid Kornspan
David Kornspan
RLRegina Lubkovskaia
Regina Lubkovskaia
Shubham MathurShubham Mathur
Shubham Mathur
AYAdva Yeheskel
Adva Yeheskel
MSMali Salmon-Divon
Mali Salmon-Divon
Brucella species are facultative intracellular bacteria that cause brucellosis, a zoonotic world-wide disease. The live attenuated B. melitensis Rev.1 vaccine strain is widely used for the control of brucellosis in the small ruminant population. However, Rev.1 induces antibodies against the O-polysaccharide (O-PS) of the smooth lipopolysaccharide thus, it is difficult to differentiate between infected and vaccinated animals. Hence, rough Brucella strains lacking the O-PS have been introduced. In the current study, we conducted a comprehensive comparative analysis of the genome sequence of two natural Rev.1 rough strains, isolated from sheep, against that of 24 Rev.1 smooth strains and the virulent reference strain B. melitensis 16M. We identified and characterized eight vital mutations within highly important genes associated with Brucella lipopolysaccharide (LPS) biosynthesis and virulence, which may explain the mechanisms underlying the formation of the Rev.1 rough phenotype and may be used to determine the mechanism underlying virulence attenuation. Further complementation studies aimed to estimate the specific role of these mutations in affecting Brucella morphology and virulence will serve as a basis for the design of new attenuated vaccines for animal immunization against brucellosis.

22 December 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
JQJuan Sebastian Quintero-Barbosa
Juan Sebastian Quintero-Barbosa
YSYufeng Song
Yufeng Song
FMFrances Mehl
Frances Mehl
Shubham MathurShubham Mathur
Shubham Mathur
LLLauren Livingston
Lauren Livingston
Steven ZeichnerSteven Zeichner
Steven Zeichner
Background/Objectives: New vaccine platforms that rapidly yield low-cost, easily manufactured vaccines are highly desired, yet current approaches lack key features. We developed the Killed Whole-Cell/Genome-Reduced Bacteria (KWC/GRB) platform, which uses a genome-reduced Gram-negative chassis to enhance antigen exposure and modularity via an autotransporter (AT) system. Integrated within a Design–Build–Test–Learn (DBTL) framework, KWC/GRB enables rapid iteration of engineered antigens and immunomodulatory elements. Here, we applied this platform to the HIV-1 fusion peptide (FP) and tested multiple antigen engineering strategies to enhance its immunogenicity. Methods: For a new vaccine, we synthesized DNA encoding the antigen together with selected immunomodulators and cloned the constructs into a plasmid. The plasmids were transformed into genome-reduced bacteria (GRB), which were grown, induced for antigen expression, and then inactivated to produce the vaccines. We tested multiple strategies to enhance antigen immunogenicity, including multimeric HIV-1 fusion peptide (FP) designs separated by different linkers and constructs incorporating immunomodulators such as TLR agonists, mucosal-immunity-promoting peptides, and a non-cognate T-cell agonist. Vaccines were selected based on structure prediction and confirmed surface expression by flow cytometry. Mice were vaccinated, and anti-FP antibody responses were measured by ELISA. Results: ELISA responses increased nearly one order of magnitude across design rounds, with the top-performing construct showing an ~8-fold improvement over the initial 1mer vaccine. Multimeric antigens separated by an α-helical linker were the most immunogenic. The non-cognate T-cell agonist increased responses context-dependently. Flow cytometry showed that increased anti-FP-mAb binding to GRB was associated with greater induction of antibody responses. Although anti-FP immune responses were greatly increased, the sera did not neutralize HIV. Conclusions: Although none of the constructs elicited detectable neutralizing activity, the combination of uniformly low AlphaFold pLDDT scores and the functional data suggests that the FP region may not adopt a stable native-like structure in this display context. Importantly, the results demonstrate that the KWC/GRB platform can generate highly immunogenic vaccines, and when applied to antigens with well-defined native tertiary structures, the approach should enable rapidly produced, high-response, very low-cost vaccines.

23 December 2022 in Microbiology Research
Verified
Journal Article
Open access
PDF file
Shubham MathurShubham Mathur
Shubham Mathur
SBSvetlana Bardenstein
Svetlana Bardenstein
DCDani Cohen
Dani Cohen
MBMenachem Banai
Menachem Banai
Serological diagnosis provides a robust and effective approach to monitoring and controlling small ruminant brucellosis. Brucella melitensis Rev. 1 is a live vaccine strain used in prophylactic vaccination against small ruminant brucellosis. Because the vaccine strain shares identical serological antigens with the corresponding field strains, differentiating infected from vaccinated animals (DIVA) serological responses hamper surveillance campaigns and interventions that involve vaccination. We have developed a serum PCR-based approach in which we amplify and sequence Brucella omp2a as a DIVA solution and tRNA (uracil-5-)-methyltransferase as a species marker in the serum samples to determine the etiological agent involved in brucellosis field cases. Using this method, we identified the involvement of both the Rev. 1 vaccine strain and a field strain in an outbreak of brucellosis in a flock. This method represents a novel approach in studying the etiology of brucellosis using serum samples as a source of the pathogen’s DNA.

5 February 2026 in Viruses
Verified
Journal Article
Open access
PDF file
JQJuan Sebastian Quintero-Barbosa
Juan Sebastian Quintero-Barbosa
YSYufeng Song
Yufeng Song
FMFrances Mehl
Frances Mehl
Shubham MathurShubham Mathur
Shubham Mathur
LLLauren Livingston
Lauren Livingston
Steven ZeichnerSteven Zeichner
Steven Zeichner
Background: Killed Whole Cell Genome-Reduced Bacteria (KWC/GRB), a versatile vaccine platform, can produce very low cost, thermostable, easily manufactured vaccines expressing complex immunogens that include potent immunomodulators. This system supports iterative optimization through a Design–Build–Test–Learn (DBTL) workflow aimed at enhancing immunogenicity. We applied this approach to developing HIV-1 gp41 Membrane-Proximal External Region (MPER) vaccines using the scaffolded MPER antigen, 3AGJ, a recombinant heterologous protein engineered to mimic MPER structures recognized by broadly neutralizing monoclonal antibodies (bNAbs). Methods: Five KWC/GRB vaccines expressing versions of 3AGJ were designed, including versions linked to immunomodulators and multimers of the immunogen. Display on the surface of the bacteria was evaluated by flow cytometry using the broadly neutralizing monoclonal antibody 2F5. Outbred HET3 mice were vaccinated intramuscularly, and MPER-specific antibody responses were assessed by ELISA and by the ability of the vaccines to induce neutralizing antibodies. Neutralization was measured against tier 1 and tier 2 HIV-1 pseudoviruses. Results: All five vaccines were strongly expressed on the bacterial surface and induced clear MPER-specific antibody responses in every mouse. About 33% of the animals showed detectable HIV-1 neutralization. Conclusions: These results demonstrate that a KWC/GRB-based scaffold-MPER (3AGJ) vaccine can elicit HIV-1 neutralizing antibodies in a subset of animals. Although further optimization will be required to improve the consistency and magnitude of neutralizing responses, the findings provide an initial validation of the concept. There are many strategies that can be used to enhance and extend immune responses induced by KWC/GRB vaccines that can be employed to yield improved anti-HIV-1 immune responses.